In the Specification

Please delete the SEQUENCE LISTING submitted on 26 April 2001, and replace such deleted sequence listing with the enclosed replacement SEQUENCE LISTING.

Please delete the section entitled "BRIEF DESCRIPTION OF THE FIGURES" at page 2, lines 1-20 of the specification, and replace such deleted section with the following replacement section.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents the nucleotide sequence of a human TRAIL receptor DNA fragment (SEQ ID NO:3), as well as the amino acid sequence encoded thereby (SEQ ID NO:4). This DNA fragment is described in Example 3.

Figure 2 presents the results of the assay described in example 7. In the assay, a soluble TRAIL-R/Fc fusion protein blocked TRAIL-induced apoptosis of Jurkat cells.

Figure 3 presents the results of the experiment described in example 8. The indicated compounds were demonstrated to inhibit apoptosis of cells expressing TRAIL receptor.

Figures 4A to 4C depict targeted insertion of a neo cassette into the Sma I site of the μ1 exon. The construct was employed in generating transgenic mice, as described in example 10. Figure 4A is a schematic diagram of the genomic structure of the μ locus. The filled boxes represent the μ exons. Figure 4B is a schematic diagram of the CmD targeting vector. The dotted lines denote those genomic μ sequences included in the construct. Plasmid sequences are not shown. Figure 4C is a schematic diagram of the targeted μ locus in which the neo cassette has been inserted into μ1.

Figures 5A and 5B present the nucleotide sequence (SEQ ID NO:6) of a vector designated pGP1k, as described in Example 11 below.

In the Claims

Please cancel claims 1-37 and 39, amend claim 38 by rewriting it as shown below, and add the following claims (40-73). Claims 40-73 are supported generally throughout the